Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Orismilast in mild to severe hidradenitis suppurativa
NCT04982432Phase 2Unknown
- Start
- Oct 2021
- Primary completion
- Dec 2022
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of orismilast in hidradenitis suppurativa (HS). Primary endpoint: Percent change from Baseline in Abscesses and Nodules count at 16 weeks. Status: unknown.
02
Drugs
orismilast
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on NCT04982432.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04982432.